On October 20, 2026 IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, reported the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSense cryoablation for the local treatment of low-risk breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first patient in the study was enrolled at West Cancer Center & Research Institute in Germantown, Tennessee ("West Cancer Center") by Dr. Richard E. Fine, MD, FACS, Director of the Margaret West Comprehensive Breast Center and lead author of the ICE3 Study on cryoablation of small, low-risk breast cancer.
The second patient was enrolled at Adventist Health Glendale in Glendale, California ("Adventist Health Glendale"). The site is led by Dr. Dennis Holmes, MD, FACS, a breast surgeon and recognized authority in breast cancer cryoablation.
These initial enrollments follow the Company’s efforts to establish a network of U.S. clinical sites for the ChoICE Study. In August 2026, both West Cancer Center and Adventist Health Glendale announced their eligibility to enroll patients after signing a site agreement and receiving IRB approval. Earlier this month, IceCure announced the addition of Legacy Health’s Legacy Medical Group – Surgical Oncology at Good Samaritan Medical Center in Portland, Oregon, further expanding the ChoICE Study’s U.S. clinical network.
"Enrolling the first patients marks continued progress in the execution of our post-market strategy for ProSense," said Eyal Shamir, Chief Executive Officer of IceCure Medical. "As we continue to expand the ChoICE Study’s clinical network, we aim to generate additional real-world evidence while supporting broader clinical adoption and access to minimally invasive cryoablation for eligible patients."
The ChoICE Study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data on ProSense in its U.S. Food and Drug Administration ("FDA") cleared indication. Participating sites are expected to serve both as study centers and active commercial sites, enabling them to offer ProSense cryoablation to eligible patients who are not participating in the ChoICE Study.
(Press release, IceCure Medical, OCT 20, 2026, View Source [SID1234673620])